Lundbeck’s Vyepti gets Japan marketing authorization
Japan’s MHLW granted marketing authorization for Lundbeck’s Vyepti (eptinezumab) to help prevent migraine attacks in adults, citing global Phase III and Japan-specific studies.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Lundbeck gets Japan marketing authorization for Vyepti to prevent migraines
Lundbeck said Japan’s MHLW granted marketing authorization for eptinezumab (Vyepti) for preventing migraine attacks in adults.